Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bharvin K R Patel

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Biotechniques|May 27, 2003
One-step cellular caspase-3/7 assayRosa A Carrasco, Nancy B Stamm, Bharvin K R Patel
Molecular Cancer Therapeutics|January 11, 2011
Antisense inhibition of survivin expression as a cancer therapeuticRosa A Carrasco, Nancy B Stamm, Eric Marcusson, et al.
Oncogene|April 12, 2002
Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathwaysRegina M Day, Lilian Soon, Diane Breckenridge, et al.
American Journal of Translational Research|May 22, 2012
Biomarkers of the Hedgehog/Smoothened pathway in healthy volunteersSunil K Kadam, Bharvin K R Patel, Emma Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 14, 2003
Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimidesConcha Sanchez-Martinez, Chuan Shih, Guoxin Zhu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Blood|September 28, 2019
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myelomaMargot J Pont, Tyler Hill, Gabriel O Cole, et al.
Oncotarget|March 24, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsBruce W Konicek, Andrew R Capen, Kelly M Credille, et al.
Bioorganic & Medicinal Chemistry Letters|October 14, 2003
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitorsConcha Sanchez-Martinez, Chuan Shih, Margaret M Faul, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Biotechniques|May 27, 2003
One-step cellular caspase-3/7 assayRosa A Carrasco, Nancy B Stamm, Bharvin K R Patel
Molecular Cancer Therapeutics|January 11, 2011
Antisense inhibition of survivin expression as a cancer therapeuticRosa A Carrasco, Nancy B Stamm, Eric Marcusson, et al.
Oncogene|April 12, 2002
Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathwaysRegina M Day, Lilian Soon, Diane Breckenridge, et al.
American Journal of Translational Research|May 22, 2012
Biomarkers of the Hedgehog/Smoothened pathway in healthy volunteersSunil K Kadam, Bharvin K R Patel, Emma Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 14, 2003
Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimidesConcha Sanchez-Martinez, Chuan Shih, Guoxin Zhu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Blood|September 28, 2019
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myelomaMargot J Pont, Tyler Hill, Gabriel O Cole, et al.
Oncotarget|March 24, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsBruce W Konicek, Andrew R Capen, Kelly M Credille, et al.
Bioorganic & Medicinal Chemistry Letters|October 14, 2003
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitorsConcha Sanchez-Martinez, Chuan Shih, Margaret M Faul, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Pageof 2